<DOC>
	<DOC>NCT02805218</DOC>
	<brief_summary>The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.</brief_summary>
	<brief_title>PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Patients with age â‰¥ 18 years diagnosis of lymphoma(Hodgkin's lymphoma and nonHodgkin's lymphoma) patients Karnofsky Performance Status Z70 life expectancy of at least 8 months normal white blood cell count and platelet count Written informed consent are acquired uncontrolled infection pregnancy Have accepted any other antitumor drug within 4 weeks before anticipated the study Other situations that investigators consider as contraindication for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>